Fundz

Scenic Biotech Announces $31 Million Financing To Progress Pipeline Of Genetic Modifiers In Cancer And Rare Diseases

PRIVATEMar 10, 2022

Amount Raised

$31 Million

Round Type

Funding Round

AmsterdamBiotechnologyScience And Engineering

Description

Scenic Biotech BV ("Scenic"), a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, is pleased to announce it has closed a Series A financing of ~$31 million (€28 million).

Quick answer

Scenic Biotech raised $31 Million in a Funding Round round, dated March 10, 2022. Scenic Biotech is based in Amsterdam, North Holland, Netherlands.

How much did Scenic Biotech raise?
Scenic Biotech raised $31 Million in a Funding Round round on March 10, 2022.
What does Scenic Biotech do?
Scenic Biotech is focused on identifying genetic modifiers, a completely new class of disease targets, for drug intervention.
Where is Scenic Biotech based and how big is it?
Scenic Biotech is based in Amsterdam, North Holland, Netherlands. Fundz records about 43 employees.

Source: Fundz verified event record.

Who else raised in Science And Engineering and Biotechnology around the same time

Companies in the same sectors as Scenic Biotech that raised within 45 days of this round, from Fundz verified event records.

  • Unlearn raised $50M on April 19, 2022.
  • Carlsmed raised $30M (Series B) on April 19, 2022.
  • Unlearn raised $50M (Series B) on April 19, 2022.
  • Be Biopharma raised $130M (Funding Round) on April 14, 2022.
  • CDR-Life raised $76M (Series A) on April 13, 2022.
  • Surf Bio raised $16M (Seed) on April 12, 2022.

Who to call at Scenic Biotech, and when

A new round usually means Scenic Biotech is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Scenic Biotech raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Scenic Biotech, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Scenic Biotech. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Scenic Biotech

Location

Amsterdam, North Holland, Netherlands

About

Scenic Biotech is focused on identifying genetic modifiers, a completely new class of disease targets, for drug intervention. Also known as disease suppressors, genetic modifiers are genes that act to suppress or completely block the effect of a disease-causing mutated gene. As a pioneer in the field, Scenic Biotech is leveraging its Cell-Seq discovery platform to identify genetic modifiers across multiple therapeutic areas. It is building a pipeline of disease modifying therapeutics to treat devastating diseases including inherited rare diseases and cancer. Its lead programs include an immuno-oncology program targeting QPCTL, and three rare diseases programs based on druggable genetic modifiers. The rare disease programs consist of; Niemann Pick disease, type C (NP-C1), a rare lipid storage disorder that affects lipid metabolism, or the way fats, lipids, and cholesterol are transported in human cells, Barth syndrome, an X-linked, lipid metabolism disorder that affects the heart, and a program to treat a severe heritable metabolic syndrome. Scenic Biotech has a multi-year strategic collaboration with Genentech, a member of the Roche Group, to discover, develop and commercialize novel therapeutics that target genetic modifiers. Headquartered in Amsterdam, The Netherlands, Scenic Biotech was founded in 2017 as a spin-out of the Netherlands Cancer Institute, and Oxford University. It is backed by a pan-European syndicate of Venture Capital investors that include Eir Ventures, BioMedPartners, Vesalius Biocapital, BioGeneration Ventures, Inkef Capital and Oxford Science Enterprises. 'Scenic Biotech' refers to all companies within the Scenic group, comprising Scenic Holding BV and its two fully owned subsidiary companies: Scenic Immunology BV and Scenic Biotech BV. For further information, please visit: www.scenicbiotech.com Follow up on LinkedIn

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Scenic Biotech raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Scenic Biotech's next move

See what Strategic adds

Scenic Biotech raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.